CVS Caremark Calls For OTC Switch Ad Warnings To Match Rx
This article was originally published in The Tan Sheet
Executive Summary
A research letter published in JAMA says “closer attention” should be paid to the lack of risk information in advertising for the OTC switch versions of prescription drugs. Research sponsor CVS Caremark says OTC ads should convey the same information as Rx ads.
You may also be interested in...
People In Brief
Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.